STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Purchases 53,500 Shares

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 53,500 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was acquired at an average cost of $24.24 per share, with a total value of $1,296,840.00. Following the completion of the acquisition, the insider now directly owns 10,821,931 shares in the company, valued at approximately $262,323,607.44. This trade represents a 0.50 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Wednesday, December 18th, Broadwood Partners, L.P. bought 23,000 shares of STAAR Surgical stock. The stock was acquired at an average cost of $24.33 per share, for a total transaction of $559,590.00.

STAAR Surgical Stock Performance

Shares of STAA stock opened at $24.26 on Thursday. STAAR Surgical has a 1 year low of $23.72 and a 1 year high of $52.68. The firm has a market capitalization of $1.20 billion, a PE ratio of 55.14 and a beta of 0.59. The stock has a fifty day moving average of $28.43 and a two-hundred day moving average of $34.63.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on STAA. Stifel Nicolaus dropped their price target on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, August 26th. Canaccord Genuity Group dropped their target price on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a research report on Monday, December 9th. Stephens raised shares of STAAR Surgical to a “hold” rating in a report on Monday, December 2nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $42.83.

Institutional Investors Weigh In On STAAR Surgical

Several institutional investors have recently bought and sold shares of STAA. SG Americas Securities LLC raised its position in shares of STAAR Surgical by 173.5% during the 2nd quarter. SG Americas Securities LLC now owns 9,038 shares of the medical instruments supplier’s stock worth $430,000 after buying an additional 5,733 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of STAAR Surgical by 3.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,343 shares of the medical instruments supplier’s stock valued at $540,000 after buying an additional 418 shares in the last quarter. Louisiana State Employees Retirement System increased its holdings in STAAR Surgical by 2.1% in the second quarter. Louisiana State Employees Retirement System now owns 24,700 shares of the medical instruments supplier’s stock worth $1,176,000 after buying an additional 500 shares during the last quarter. Slow Capital Inc. raised its position in STAAR Surgical by 3.1% during the second quarter. Slow Capital Inc. now owns 67,649 shares of the medical instruments supplier’s stock valued at $3,221,000 after acquiring an additional 2,003 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in STAAR Surgical by 1.4% in the second quarter. Bank of New York Mellon Corp now owns 405,222 shares of the medical instruments supplier’s stock valued at $19,293,000 after acquiring an additional 5,712 shares during the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.